Advertisement
News
Advertisement

Data to be presented at this week's EuroPCR 2012 congress, Paris

Sun, 05/13/2012 - 11:45pm
The Associated Press

MENLO PARK, Calif.--(BUSINESS WIRE)--May 14, 2012-- ReCor Medical , an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with 'resistant' hypertension ("HTN"), a major risk factor for cardiovascular disease.

Current results of the study will be presented from the podium on Thursday, May 17, 08:00-10:20, Room 241, Palais des Congres, by principal investigator Thomas A. Mabin, M.D., Vergelegen Medi-Clinic, South Africa.

Preliminary clinical data for PARADISE were previously reported by Dr.

Mabin at the recent "TRenD 2012" transcatheter renal denervation scientific meeting. The PARADISE data showed that systolic blood pressure was reduced by an average of31 mm Hg in 7 patients at 60-days follow-up. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

"ReCor's PARADISE system is designed to provide a minimally invasive ultrasound therapy to resistant hypertension patients to help reduce their blood pressure," said Mano Iyer, President & CEO, ReCor Medical.

"In the REDUCE study, we have been able to show that our novel PARADISETM system is capable of safely and quickly denervating patients, resulting in sustained blood pressure reductions out to 6 months. We look forward to Dr. Mabin's reporting of the current results of our REDUCE pilot clinical trial at PCR as we move forward with our launch of our PARADISETM system in Europe." About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology.

ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company's PARADISE(TM) technology for renal denervation is CE-marked.

For more information about ReCor Medical, please visit the Company's website at www.recormedical.com.

NOTE: PARADISE(TM) is approved for sale in Europe; it is not approved for sale or investigational use in the United States.

CONTACT: Media: Ronald Trahan Associates Inc.

Ronald Trahan, 1-508-359-4005, x108 APR, President KEYWORD: UNITED STATES EUROPE NORTH AMERICA CALIFORNIA FRANCE INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES OTHER HEALTH GENERAL HEALTH SOURCE: ReCor Medical, Inc.

Copyright Business Wire 2012 PUB: 05/14/2012 03:00 AM/DISC: 05/14/2012 03:00 AM http://www.businesswire.com/news/home/20120514005465/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading